Abstract: A method includes forming a lower semiconductor region, forming an upper semiconductor region overlapping the lower semiconductor region, forming a lower gate dielectric and an upper gate dielectric on the lower semiconductor region and the upper semiconductor region, respectively, forming a lower gate electrode on the lower gate dielectric and the upper gate dielectric, etching back the lower gate electrode, forming a gate isolation layer on the lower gate electrode that has been etched back, and forming an upper gate electrode over the gate isolation layer. The upper gate electrode is on the upper gate dielectric.

Abstract: The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. Compounds of the disclosure have activity as dual modulators of Janus kinase (JAK), alone, or in combination with one or more of an additional mechanism, including a tyrosine kinase, such as TrkA or Syk, and PDE4, and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK and PDE4 by administering a compound herein described.

Abstract: High resolution 3D thermal imaging can be obtained by using enhanced non-destructive heat transducer designs. A thermal property measurement method includes providing a sample for thermal property measurement, and bonding a transducer layer on the sample through a temporary bonding layer. Thermal measurement processes are performed along the X-Y, X-Z and Y-Z planes of the sample, wherein the X-Y plane is parallel to a top surface of the sample, and the X-Z plane and Y-Z plane are perpendicular to the top surface of the sample. Each thermal measurement processes include heating a designated region of the sample covered with the transducer layer using a pump laser, and using a probe laser for generating a reflectance signal of the sample, and determining a thermal conductivity in the designated region of the sample from the reflectance signal. Furthermore, the transducer layer is removed along with the temporary bonding layer from the sample.

Abstract: Semiconductor structures and method of forming the same are provided. A method according to the present disclosure includes providing an intermediate structure that includes an opening, conformally depositing a metal liner over the opening, depositing a dummy fill material over the metal liner, recessing the dummy fill material such that a portion of the metal liner is exposed, removing the exposed portion of the metal liner, removing the recessed dummy fill material, and after the removing of the recessed dummy fill material, depositing a metal fill layer over the opening.

Abstract: A method includes forming a first de-bond structure over a first substrate, where forming the first de-bond structure includes depositing a first de-bond layer over the first substrate, depositing a first silicon layer over the first de-bond layer, depositing a second de-bond layer over the first silicon layer, and depositing a second silicon layer over the second de-bond layer, epitaxially growing a first multi-layer stack over the first de-bond structure, bonding the first multi-layer stack to a second multi-layer stack, and performing a first laser annealing process to ablate the first silicon layer and portions of the first de-bond layer and the second de-bond layer in order to de-bond the first substrate from the first multi-layer stack.

Abstract: A method includes forming a bonding structure that contains thermal conductive vias (also termed as thermal vias, thermal conductive pillars, or thermal pillars) on a semiconductor structure. The thermal vias, with material thermal conductivity greater than about 10 W/m·K, are embedded in the bonding structure that provides a quick dissipation path of heat from thermal hotspot regions into a substrate.

Abstract: The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. Compounds of the disclosure have activity as dual modulators of Janus kinase (JAK), alone, or in combination with one or more of an additional mechanism, including a tyrosine kinase, such as TrkA or Syk, and PDE4, and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK and PDE4 by administering a compound herein described.

Abstract: The present invention describes novel boron containing pyrazole compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described are methods of treating inflammation, auto-immune diseases, cancer, and other conditions that are susceptible to the inhibition of a Janus kinase by administering a compound herein described.

Abstract: The present invention relates to solid forms of a substituted benzoxaborole compound, specifically crystalline forms of a compound of formula I, compositions comprising crystalline forms of the compound of formula (I), and methods of their use.

Abstract: A method for determining parameters of nanostructures, wherein the method includes steps as follows: Firstly, an X-ray reflection intensity measurement curve of a nanostructure to be tested is obtained by radiating the nanostructure to be tested with X-ray. The X-ray reflection intensity measurement curve is compared with an X-ray reflection intensity standard curve to obtain a comparison result. Subsequently, at least one parameter existing in the nanostructure to be tested is determined according to the comparison result.

Abstract: A benzoxaborole formulation composition including a benzoxaborole, a non-ionic surfactant, or a non-ionic and ionic surfactant mixture, and a carrier is described herein. At least one of the non-ionic surfactant, the non-ionic and ionic surfactant mixture, and the carrier comprise a Lewis base or a N—H or O—H bond. The carrier is a solid or a liquid. Benzoxaborole compounds and methods of using the compounds and formulations of the compounds are described. For example, a method for reducing, preventing, ameliorating, or inhibiting an infestation by a pathogen by applying a compound or a formulation of a compound, wherein the pathogen is selected from insects, nematodes, bacteria, microbes, fungi, protozoa, viruses, and parasites, or any combinations thereof is described.

Abstract: The present invention describes novel boron containing pyrazole compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described are methods of treating inflammation, auto-immune diseases, cancer, and other conditions that are susceptible to the inhibition of a Janus kinase by administering a compound herein described.

Abstract: The present invention provides a pharmaceutical composition and method for having cytotoxic activity to interact with cancer cells and destroy the cancer cells.

Abstract: The present invention relates to solid forms of a substituted benzoxaborole compound, specifically crystalline forms of a compound of formula I, compositions comprising crystalline forms of the compound of formula (I), and methods of their use.

Abstract: The present invention relates to solid forms of a substituted benzoxaborole compound, specifically crystalline forms of a compound of formula I, compositions comprising crystalline forms of the compound of formula (I), and methods of their use.

Abstract: The present invention relates to methods of preparing benzoxaboroles. Benzoxaborole compounds have shown promise as antimicrobial agents, especially against fungal pathogens. The invention also relates to compositions of acyclic alkoxy boronic acid esters as intermediates, and continuous flow processes of mixing the intermediates with organomagnesium, magnesium, or organolithium reagents to form the desired benzoxaboroles.

Abstract: The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.

Abstract: The present invention describes novel boron containing pyrazole compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described are methods of treating inflammation, auto-immune diseases, cancer, and other conditions that are susceptible to the inhibition of a Janus kinase by administering a compound herein described.

Abstract: The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.

Abstract: The present invention relates to solid forms of a substituted benzoxaborole compound, specifically crystalline forms of a compound of formula I, compositions comprising crystalline forms of the compound of formula (I), and methods of their use.